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1. Introduction 
Meningiomas account for 16%-25% of all intracranial tumors, and quite often they rank 
amongst the most frequent neuro-oncological diagnostic subgroups in European or 
American registries (4, 5, 8, 54) As regards their natural history, (23, 29, 46, 55, 56, 59, 61) the 
few reported series of conservatively managed symptomatic meningiomas–bearing 
adequate FU- have documented a consistent progression in approximately one-third of 
patients, although in a wide spectrum of variability (TABLE 1). 
The average annual incidence is 5-6 new cases per 100,000 (F/M ratio roughly 3:1) and it is 
lower in pediatrics, even though younger patients may show quite malignant oncotypes (4, 
5, 8, 24, 43, 46, 59, 61, 64, 71, 73, 81). However, younger patients may show quite aggressive 
oncotypes (64, 71, 73). Growing human, sanitary and social costs are more pronounced in 
females because of the quoted demographic data.  
At uni-multivariate analysis, the main factors putatively associated with more- or-less 
pronounced aggressiveness seem to be represented by younger age and T2-hyperintensity, 
or by presence of calcifications, respectively (TABLE 1). As expected, grade 2 and 3 
meningiomas entail a more severe prognosis (30, 39, 40, 48, 51, 56, 62), thereby justifying  the 
advocated multidisciplinary treatments in such instances  ( 30, 54 62, 84,85 ). 
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2. Treatment options 
Surgery still represents the mainstay in the specific neurosurgical armamentarium. Indeed, 
whenever feasible, a Simpson grade 1 resection of the tumor should  be considered the 
golden therapeutic standard,  reducing immediately any mass effect, and alleviating clinical 
signs and symptoms (2, 10, 11, 33, 41, 45, 52- 54 , 75, 80). 
 
Author 
(year)  
(Reference) 
No. of 
patients 
Mean 
follow-up 
(mo) 
No. (%) 
showing 
growth 
Average 
growth rate 
Factors 
commonly 
associated with 
an aggressive 
cell kinetic 
Factors 
commonly 
observed in 
resting tumors 
Olivero et 
al. (1995) 
(61)  
45 32 10 (22.2) 2.4 mm/year     
Go et al. 
(1998) (23)]  
35 74 4 (11.4) 3.2 mm/year   Calcification 
Kuratsu et 
al. (2000) 
(43) 
63 27.8 20 (31.7)   
T2 
hyperintensity 
Calcification 
Niiro et al. 
(2000) (59) 
40 41.8 14 (35)   
Larger size, T2 
hyperintensity, 
male sex 
Calcification 
Yoneoka et 
al. (2000) 
(81) 
37 50.4 9 (24.3) 1.36 cm3/year 
Younger age, 
larger tumors 
  
Nakamura 
et al. (2003) 
(55)  
41 43 14 (34) 0.796 cm3/year 
Younger age, T2 
hyperintensity 
Calcification 
Herscovici 
et al. (2004) 
(29) 
43 67 16 (37) 4 mm/year 
Younger age, 
sphenoid ridge 
Calcification, 
smaller tumors 
Yano and 
Karatsu 
(2006) (80)  
67 >60 25 (37.3) 1.9 mm/year 
T2 
hyperintensity 
Calcification 
Table 1. Natural history of meningiomas. Reported growth rates in conservatively treated 
series. 
In facts, local recurrence rates at 10 year-follow up are directly related to Simpson’s grade of 
radicality, with 10-33% after complete resection (Simpson 1-2), and 55-75% after partial-to-
minimal removal (i.e. Simpson 3-6) (33, 45, 48, 52, 53, 75, 80). This seems particularly true in 
the vast majority of convexity meningiomas, whereas results are less warranted in critical 
locations, like in skull base tumors.   
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Indeed, despite surgical advances, whenever these tumors are infiltrating the skull base, 
cranial nerves, or vascular structures, complete resection may not be feasible without 
unacceptable morbidity and sometimes mortality rates. Considering some of the largest 
published series, gross total removal of basal meningiomas sounds achievable in 60%-
87.5% of the patients with 30%-56% of severe complications - particularly frequent in grade 
2-3 histotypes - and a median postoperative mortality rate of 3.6 % (0%-9%) (11, 12, 45, 48, 
75, 76, 79, 80). The main factors conditioning the extent of removal in skull base locations 
have been extensively analyzed in the literature, thereby creating the “resectability 
grading” where the final score represents the sum of each of the most relevant limiting 
factors: from cranial nerve involvement to vessel encasement, from extrafossa invasion to 
previous radiation treatments (45, 63, 74, 78, 82, 86). 
 
Table 2a. (53, 10, 77) 
 
Table 2b. (83, 53, 10, 77) 
Table 2. Meningiomas: analysis of recurrence rate after gross total removal (GTR: TABLE 2a) 
compared to subtotal removal (STR: TABLE 2b) 
The observed wide spectrum of recurrence rates (from 0 to 17%), is seemingly linked not 
only to the pre-existing W.H.O.’s and Simpson’s grade, but also to the duration of follow up 
periods, although the latter is an often disregarded/underestimated parameter in the 
literature (10, 53, 69, 70, 75, 76, 79). 
The non negligible problems with surgical radicality in crucial sites, may be further 
complicated by the presence of „aggressive“ cytotypes, most often responsible for early 
recurrences shortening patients‘ survival (TABLE 2&3). 
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Author (ref) Period N.Pts Mal. Definition Survival 
Harris (27) 1987-2001 12 WHO 2000 59% 5yr 
    0% 10 yr 
Perry (64-65) 1970-1997 27 Frank anaplasia 32% 5yr 
Hug (30) 1973-1995 16 WHO 1993 51% 5yr 
Palma (62) 1951-1986 29 WHO 1993 64% 5yr 
    35% 10 yr 
Ware (84) 1988-2002 17 WHO 1993 59% 5 yr 
    15% 10 yr 
Ojemann (60) 1991-1999 22 WHO 1993 40% 5 yr 
Goldsmith (24) 1967-1990 23 Unique grading scheme 58% 5 yr. 
Table 3. Recently published series of malignant meningiomas: 5- 10 yr survival. 
Finally, also the tackling issues of meningiomatosis, contribute to explain the special 
momentum of combined, multidisciplinary approaches including Gamma Knife Radio 
Surgery (GKR). 
3. Gamma knife radiosurgery 
The fundamental reasons for the growing role of this technique, particularly in highly 
critical intracranial meningiomas, may be briefly summarized as follows:  
1. fine tuning of the dosimetry planning. With the advent of hardware and software 
stereotactic sophistication, the process of 3D recognition of the tumor – as well as to 
spare the adjacent critical structures has gradually become more and more refined. A 
major role to this regard has been played by image co-registration, morpho-functional 
integration (functional MRI / spectroscopy, specific metabolic PET scan mapping etc.) 
on one side, and by the use of “hybrid shots” with the new “Perfexion” whenever 
dealing with crucial targeting (7, 36, 50, 57, 58, 66). 
2. the introduction of dedicated algorhitms accurately “driving” the dose planning 
system, with probabilistic models including stockastic monitoring, quadrature-sum 
analysis (20) and linear-quadratic formalisms (32). These techniques, and the 
concomitant diffusion of phantom studies, have repeatedly confirmed the reliability of 
such referrals, consistently improving the main conformity indexes. To date, the 
recommended “surface- or “peripheral “doses” for meningiomas range from 11 - to - 15 
Gy (16, 36, 37, 41, 47, 49, 54, 72). 
The “ideal” – i.e. the most biologically justified – targeting dose- volume in these peculiar 
lesions, is still a matter of debate, with a spectrum of options: from including “only” the 
gross, T1 contrast enhancing tumor, plus a supposedly infiltrated margin of a few mm 
(39,40,50), up to the controversial inclusion either of the “dural tail”, or of the hyperostotic 
bone. However, the former - according to extremely refined studies – has been shown to be 
essentially composed by hypervascular dura with surprisingly none of the expected tumor 
colonies (34). The latter - according to Pieper- should be almost constantly (25/26 cases) 
infiltrated, even in presence of negative imaging (67). In these cases, ablative radiosurgery 
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on the hyperostotic bone might have the same meaning of Simpson’s grade 1 in surgical 
approaches (67). 
3. a deeper radiobiological experience. Radiosurgery, like most radiation treatments, 
hitting the biological target, results in the formation of free radicals as electrons are 
freed from their atoms. Their main in vivo effect is closely related to a variety of local 
conditions: first of all the particular oncotype and its cellular peculiarities (“alpha-
beta ratio” (35), superoxide-enzyme characterization, sister–chromatide exchange 
potential etc.) defining the radio-sensitivity; then the quality and quantity of radiation 
dosimetry, the targeted volume etc., up to the microscopic model of energy 
deposition. On the basis of these features, meningiomas mostly belong to relatively 
radiosensitive, “late responding tissues” (LRT) frequently exploiting local hypoxic 
shields (3, 13, 30, 49), particularly in the elderly (59). 
As a consequence effective dosages are in the lower range, not far from normal cell 
radiosensitivity thresholds, whilst the time-interval for the effect is close to maximum in 
vivo doubling time (3, 7, 16, 31, 68, 69, 70, 71, 72). 
- At present, over half a million people have been treated by GKR all over the world, at a 
continuously increasing annual rate (in 2010 roughly 50,000 patients), with intracranial 
meningiomas actually representing approximately one third of these patients. 
It is generally accepted that the putative mechanism of action of SRS is intimately 
dependent not only upon the mentioned technical variables (dose-volume integral, 
timing, target cytology), but as well as upon the goal we are pursuing (“tumor growth 
control”, necrotic evolution, “ephaptic block“ etc.) (38, 39, 40). As regards meningiomas, 
routine protocols are focused on “Tumor Growth Control” (TGC) probably obtained 
through a combined mechanism: 1. Direct cytotoxicity, presumably promoting apoptosis; 
2. Damage to the neoplastic vascular supply, mediated by inhibited growth factors (VEGF, 
EGF, Factor 8th etc.) 3. Inactivation/destruction of hormonal receptors (e.g. Octreotide- r) 
(57, 58). Moreover, it should be stressed that meningiomas located in highly 
vascularized-oxygenated regions of the brain (cavernous sinus, sagittal sinus etc), due 
to still poorly known mechanisms (e.g. mutilation of the the superoxide dismutase 
chain etc.) usually exibit a more pronounced radiosensitivity, with sometimes spectacular 
results (Fig. 1). 
If we examine clinical and radiological results in the largest published series of intracranial 
meningiomas treated during the last decade with different radiosurgical techniques (TABLE 
4), some qualifying tenets of these therapeutic approaches appear certainly significant and 
reliable. 
A. The overall neuro-radiological results are rewarding and stable. Unfortunately, the 
available literature is of poor statistical quality, also because of the difficulties in 
performing prospective randomized, adequately stratified clinical trials. Therefore most 
comparative analyses are based on EBM Class III Data, with only a few studies 
presenting Class II informations. However, given the definition of “Local Tumor 
Control” as a post-treatment computerized target volume equal-to or smaller than the 
original, the 5yr actuarial Tumor Control Rates after GKRS range from 86.2% to  
97.9%. 
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Fig. 1. Left cavernous sinus meningioma before (top) and two years after GKRS. Note the 
drastic shrinkage of the tumor, not unusual in these locations.  
Furthermore, in GKR treated patients, primary or “imaging diagnosed” meningiomas 
share a significantly higher 5yr-PFS (87%-95%) than recurrences (34%-97%).  
B. Clinical outcome usually matches these observations, also in our experience (122). 
Adopting the concept of clinical improvement as the resolution of neurological 
symptoms, and/or increased pre-operative performances, the vast majority of cases 
shows stable or improved KPS and neurological gradings at 5-7 years or longer FU. A 
recent review published by the Pittsburgh Gamma Knife Center (39, 40) confirms in a 
cohort of 972 patients, with a long term follow up (for some of them up to 20 years) an 
overall tumor control rate up to 97% a definitively low overall morbidity rate (7.7%) 
slightly higher for crucial locations such as the cavernous sinus and petroclival region. 
As a rule, the cytological grading is the main determinant of the radiosurgical effectiveness. 
Malignant meningiomas maybe extremely aggressive (Fig. 2) – as mentioned above, with 
marked endovascular infiltration and neoangiogenesis, requiring multimodality 
management that include resection, fractionated radiation therapy, brachytherapy, and 
proton-photon therapy (84, 85, 86). 
Similarly, patients with benign histotypes (gr. 1) are usually characterized by 5yr actuarial 
tumor control rates (87%-96%) much higher than those with atypic (49%-77%) or anaplastic 
(0%-19%) lesions (21, 24, 37, 49, 63, 73, 77). As shown in (TABLE 4), the still limited number 
of reports with a mean follow up period of 7-10 years have consistently confirmed these 
differential LTC levels (3, 15, 41, 63, 70) 
www.intechopen.com
 
Radiosurgical Treatment of Intracranial Meningiomas: Update 2011. 
 
51 
Pubblication 
Year 
 Authors Group No. Pts. SRS 
technique
LTC % 
 (5 yr) 
1994 Goldsmith et al 
(24) 
San Francisco 
(USA) 
140 (117 benign, 23 
malignant) 
Proton 
Beam 
89 (ben), 
48 (mal) 
1998 Hakim et al (26) Boston (USA) 127 (155 tumors, of 
which 106 benign)
LINAC 89.3 for the benign 
tumors 
2001 Pendl et al 63  Graz (Austria) 197 (198 tumors) GK 98 (for 164 
patients) 
2001 
Stafford et al 77 Rochester 
(USA) 
190 (206 tumors) GK 93 for the benign, 
68 for the atypical 
and 0 for the 
malignant tumors 
at 5 years 
2002 Eustacchio et 
al18 
Graz (Austria) 121 GK 98.3 
2002  Nicolato et al 58 Verona (Italy) 122 GK 96.5 at 5yr 
2003 Chang et al1 6 Seoul (Korea) 179 (194 tumors) GK 97.1 
2003 Pollock et al 69-70 Rochester 
(USA) 
330 (356 tumors) GK 94 
2004 DiBiase et al 13 Camden (USA) 137 GK 86.2 at 5 yr 
2005 Friedman et 
al.21 
Gainesville 
(USA) 
210 LINAC
 
96 for benign, 
77 for atypical and 
19 for malignant 
tumors at 5 yr 
2005 Kreil et al41 Graz (Austria) 200 GK 98.5 at 5yr 
2005  Malik et al49 Sheffield 
(United 
Kingdom) 
277 (309 tumors) GK 87 (typ), 49 (atyp), 
0 (mal) at 5 yr 
2007 Feigl et al19 Hannover 
(Germany) 
211 (243 tumors) GK 86.3 at 4yr 
2007 Hasegawa et 
al128 
Komaki, 
(Japan) 
115 GK 87 at 5 yr 
2007 Kollová et al37 Prague (Czech 
Republic) 
368 (400 tumors) GK 98 at 5 yr 
2008 Iwai et al31 Osaka (Japan) 108 GK 93 at 5 yr 
2008 Kondziolka et 
al139-40 
Pittsburgh 
(USA) 
972 (1,045 tumors) GK 97 (ben) at 5yr 
2009 Colombo et al19 Vicenza (Italy) 199 CyberKnife 93.6 at 5yr 
2009 Takanashi et 
al178 
Sapporo 
(Japan) 
101 GK 
 
95.5% in cav.sin. 
98.4% in post.fossa 
Table 4. GKR-, PROTON BEAMLINAC- and Cyberknife-based stereotactic radiosurgery in 
meningiomas. Synopsis of the largest published series of the last two decades comparing 
local tumor control rates. 
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Anaplastic (Gr. 3) Meningioma
 
Fig. 2. Anaplastic (gr.3) meningioma. Note the pronounced endo-perivascular tumor cell 
coating. 
Furthermore, it is worth stressing that – even treating larger volumes – either with reduced 
dosages or with fractionated schedules, the literature shows no evidence of significantly 
increased “Adverse Radiation Effects” (“ARE”). Probably because the risk of “ARE” 
gradually subsides with lower prescription doses (3, 18, 19, 22, 31, 38, 47, 49, 64, 65, 70). 
C. Nonetheless, also in meningioma radiosurgical treatments, several limits, pitfalls and 
risks remain to be tackled. Quoting some of the most intriguing: 
a. The satellite edema, particularly pronounced in the convexity regions or in 
parasagittal locations and rarely documented in skull base tumors, probably 
represent the dominant figure in the early stages of the “Peritumoral Imaging 
Changes”. The main conditioning factors that may heavily influence the severity of 
these processes, are essentially related to the specific radiosurgical parameters: e.g. 
dose volume integral, conformity index etc. (6, 20, 22, 56, 72, 83, 86) However, 
recent reports have emphasized the extremely high chances to maintain adequate 
LTC rates – without increasing side effects- by treating larger meningiomas with 
either fractionated schedules or reduced dosages (3, 13, 18, 19, 22, 24, 31, 32).  
b.  the controversial or disappointing results obtained in atypic and anaplastic lesions 
(17, 25, 27, 30, 51, 73), sometimes characterized by intra- or extraneuraxis 
metastatization (17) or by enhanced growth after radiosurgery (6, 14, 42); 
c. the still pronounced morbidity rate of this technique on sensory nerves (6, 14, 77). 
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d. finally, potential problems with undue hotspots on strategic vessels within the 
dosimetry area (1, 15). 
D. A comparative analysis of Cyberknife-based (9,44) radiosurgical experiences in 
meningiomas versus GKR experiences clearly shows that follow up period is longer for 
GKR – several reports reaching 8-10 years mean FU vs. 5-6 years for Linac series. 
Targeted tumor volumes are extremely variable with both approaches, whereas the 
relative marginal dosages (12-15 Gy) as well as the tumor control rates (usually over 
90%) are quite similar. The incidence of sequelae with both techniques is quantitatively 
(3-13%) and qualitatively reasonable, severe neurological worsening is extremely rare, 
with no reported mortality. 
E. Oncogenicity. The relative risk of carcinogenesis after radiosurgery in the central 
nervous system has been calculated by means of probabilistic methods, and varies from 
1.57 to 8.75 for a dose of 1 Gy, increasing in time up to 18.4 between 20 and 25 years (7, 
55). The long-term (30 year) risk of newer radiation induced tumors in meningioma 
patients has been estimated in 1 per 1,000 treated patients (4, 5, 24, 42, 55). The natural 
incidence of new gliomas in the population (1/10,000 every year), and the number of 
meningiomas treated over 3 decades with SRS worldwide (75,000) must be the basic 
reference for any reliable statistical evaluation. As a consequence, the so far extremely 
rare (4 cases) reported instances of malignant brain tumors diagnosed in SRS - treated 
meningioma patients are probably an underestimation of the real incidence, that, 
however, does not seem to defray further development of this technique.  
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